
Opioid use in pregnancy and Neonatal Opioid Withdrawal Syndrome (NOWS)

Morissa Ladinsky, MD
Assoc. Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
UAB










US: 23,518 deaths 8.2 per 100,000

US/Alabama 2019 Drug Threat Assessment





Objectives

- 1. Understand the magnitude, medicine and scope of neonatal abstinence syndrome.
- 2. Learn concrete, data driven public health measures and best practice approaches to the immense challenge of care for opioid exposed infants.
- 3. View current and future trends in comprehensive management of NOWS.




Dopamine

- Central power driver. Essence of being human
- Memory (if DA is present, we remember it).
- Regulates how we perceive pleasure.
- Sleep and wakefulness
- Cognition (DA in frontal lobe)
- Pleasure and drive to seek it.

- Food
- Sex
- Winning a competition

- Cocaine
- Meth
- Opioids
- Heroin





Methamphetamine in pregnancy




- Low birthweight
- Shorter gestational age
- Maternal HTN/pre-e
- Abruption (10%)
- Rare reports of ICH
- Rare and brief withdrawal
- Longer term learning disability
- ADHD

"STOPPING MA AT ANY TIME DURING PREGNANCY IMPROVES OUTCOMES"


Negative outcomes on the developing child are due to the meth's effect on mother's systems.

Opioids work via specific RECEPTORS



- Brainstem: Basic life sustaining functions (sleep, breathing, HR)
- Limbic System: Emotional center (pleasure, mood, attitude)
- Cerebral Cortex
- Autonomic neurons (GI, skin, muscle)

Why do only some progress to addiction?



 Over 50% of one's propensity to addiction is under the control of our genes.

- GENETICS +
- PAST AND PRESENT ENVT+
- EXPOSURE TO THE DRUG

ACE's

•Alcoholism and alcohol abuse •Risk for intimate partner

•Risk for intimate partner violence

Chronic obstructive pulmonary disease (COPD) Multiple sexual partners

•Sexually transmitted diseases (STDs)

Depression

•Fetal death •Smoking

Health-related quality of life

Suicide attempts

•Illicit drug use

Unintended pregnancies

•Ischemic heart disease (IHD)

•Early initiation of smoking

Liver disease

Early initiation of sexual activity

Adolescent pregnancy

Maladaptive neural connections in the developing brain.

Adverse effect of early toxic stress on brain development.



Opioid/heroin dependence in pregnancy

 Developing baby experiences daily highs, lows and withdrawal.

 Withdrawal for mom is passed to developing infant.

- Premature delivery, fetal demise.
- "Pregnant women who are physically dependent on opioids should receive treatment using methadone or buprenorphine monoproduct rather than withdrawal management or abstinence."
- NIDA, ACOG, NICHD, HHS consensus 7/2016



Neonatal Opioid Withdrawal Syndrome

- The clinical findings associated with <u>opioid</u> withdrawal has been termed the neonatal opioid withdrawal syndrome (NOWS).
- Nearly all exposed infants will display some symptoms, but only a subset require treatment.

Opioid receptors concentrated in CNS and GI tract.

NAS affects baby's ability to be alert, sleep, eat, communicate cues



1 every 15 minutes

CLINICAL FEATURES

| Neurological Excitability | Autonomic Instability | Gl Dysfunction |
|---|---|---|
| Hyperirritability High-pitched inconsolable crying Agitation/Restlessness → Exoriations Difficulty sleeping Tremors Exaggerated Moro reflex Hypertonia Excessive motor activity Myoclonic jerks Uncontrolled, constant sucking Seizures (2-11%) | Apnea Bradycardia Tachypnea Nasal flaring Nasal stuffiness Temperature instablity Sweating Sneezing Mottling Yawning | Diarrhea → electrolyte disturbances, dehydration, perianal skin excoriation Hyperphagia (may require up to 150 kcal/kg/d) Regurgitation Vomiting Poor feeding Poor weight gain/FTT |

Clinical Timeline



| SUBSTANCE | ONSET (hours) | DURATION (days) | |
|----------------------|---------------|-----------------|--|
| Heroin | 24-48 | 8-10 | |
| Methadone | 48-72 | Up to 30+ | |
| Buprenorphine | 36-60 | Up to 28 | |
| Prescription opioids | 36-72 | 10-30 | |
| Polypharmacy | ?? | . 55 | |
| Fentanyl | ?? | | |



Discharge at 48 hrs???

- AAP (2014 and 2017)
- WHO (2014)
- Known fetal exposure: 4-7 days!
- 1 in 5 has onset after 48 hrs




- Withdrawal at home...
 - Poor feeing
 - Vomiting and diarrhea
 - Extreme irritability
 - Sleep challenges
 - DEHYDRATION
 - SEIZURES
 - RISK FOR CHILD ABUSE

Neonatal Abstinence Syndrome (NAS)

NAS Drug withdrawal syndrome in newborns caused primarily by *in utero* exposure to opioids. [CDC]

NAS Infants by County (2016)



Medication Assisted Treatment (MAT)

| | Buprenorphine (Subutex) | Buprenorphine/Naloxone (Suboxone) | Methadone |
|-----------|---|---|---|
| MECHANISM | Binds partially to the same opioid receptors with a longer dissociation period. | Trace doses of opioid antagonist. | Synthetic opioid agonist. Occupies same receptors but activates them very slowly. |
| IMPACT | No high. No withdrawal No craving. Clear mind. | If heroin or opioid used also, instant withdrawal symptoms. | No high, no withdrawal if used in correct doses. |

MAT Myths, New tools


MEDICATION IS NOT THE TRADING OF ONE ADDICTION FOR ANOTHER

 "People ask me all the time, 'well, aren't they just substituting one drug for another?' The answer is no. These are evidence-based treatments and they work,"

Patrice A. Harris,

Chair AMA Opioid Task Force

MAT changes the outcome





BREASTFEEDING

It Rocks!

Breastfeeding and Substance Use

- AAP committee recommends all mothers in methadone/buprenorphine treatment be allowed to breast-feed regardless of dose.
- Data suggests a protective effect on the rate of NOWS.
- HCV and HBV not contraindication for breast feeding
- HIV contraindication in developed countries



Rooming in

ROOMING-IN MAY BE ASSOCIATED WITH EVEN GREATER SAVINGS

• Decreased need for pharm Rx:

 $55\% \rightarrow 25\%$: Abrahams et al. Can Fam Physician. 2007.

45% → **11%**: Saiki *et al. Eur J Pediatr.* 2010.

 $83\% \rightarrow 14\%$: McKnight et al. Am J Perinatol. 2016.

 $46\% \rightarrow 27\%$: Holmes et al. Pediatrics. 2016.

• Decreased LOT by:

13 days: Abrahams et al. Can Fam Physician. 2007.

>5 days: Saiki et al. Eur J Pediatr. 2010.

• Decreased LOS by:

4-5 days: Saiki et al. Eur J Pediatr. 2010. Holmes et al. Pediatrics. 2016.

12 days: Abrahams et al. Can Fam Physician. 2007.

19 days: McKnight et al. Am J Perinatol. 2016.





Benefits of the Approach in this Study Site

Length of hospital stay for infants
 22.4 to 5.9 days

 Infants receiving pharmacological treatment

98% to 14%


Hospital costs per family

\$44,824 to \$10,289

No infants were readmitted for treatment of NAS and no adverse events were reported

Grossman, et al, 2017

Evolution of Federal Protections and \$\$\$\$\$



Primary Changes
in CAPTA
Related to Infants
with Prenatal
Substance
Exposure

Important to note that Tribes don't participate in the CAPTA grant thus do not make assurances regarding programs and policies

A COLLABORATIVE, NON-PUNITIVE APPROACH

Domains that might be in a Plan of Safe Care

- Primary, Obstetric and Gynecological Care
- Substance Use and Mental Health Disorder Prevention and Treatment
- Parenting and Family Support
- Infant Health and Safety
- Infant and Child Development

- Women with SUD are identified during pregnancy.
- Engaged into prenatal care, medical care, substance use treatment, and other needed services.
- Plans address the needs of BOTH INFANTS AND PARENTS/CAREGIVERS.
- NOWHERE IS REMOVAL FROM HOME A FIRST OR CRITICAL STEP.

Longitudinal effects of prenatal exposure

- Mixed results from retrospective cohort studies.
- Heterogeneity of prenatal exposure and environmental risks.
- AAP 2013 "no consensus on the effects...on cognitive abilities"

- Norwegian prospective study
- Youth age 17-22 prenatally exposed to
 - heroin alone
 - polypharmacy
 - unexposed
- Decreased cognitive ability
- Minimal executive function decline
- Envtl post natal factors + factors before birth

Comprehensive, pro-active care

- Early Intervention
- Close wraparound care

Continued recovery

Family planning



Felony Chemical Endangerment

AL Code Section 26-15-3.2

- Variable testing
- Variable enforcement
- Variable interpretation
- VARIABLE FEAR

- Avoidance of prenatal care
- Missed opportunities
- Missed cases of withdrawal





Child endangerment.





Uniform clear transparent dictate

- Accessing prenatal care will not bring incarceration.
- Disclosure of opioid use will not bring incarceration.
- Adherence to CARA will involve DHR to facilitate access to comprehensive care. Not incarceration or separation.





Better tomorrows for our kids and those who love them.



